Mechanisms of cancer-related fatigue.
暂无分享,去创建一个
Kevin Fiscella | K. Fiscella | G. Morrow | K. Mustian | J. Ryan | Jennifer K Carroll | Karen M Mustian | Gary R Morrow | Julie L Ryan | Elizabeth P Ryan | Elizabeth P. Ryan | J. Carroll
[1] R. Blakely,et al. The Proinflammatory Cytokines Interleukin-1beta and Tumor Necrosis Factor-Alpha Activate Serotonin Transporters , 2006, Neuropsychopharmacology.
[2] B. Schermer,et al. Upregulation of RGS7 may contribute to tumor necrosis factor-induced changes in central nervous function , 1999, Nature Medicine.
[3] M. Campbell,et al. Red blood cell magnesium and chronic fatigue syndrome , 1991, The Lancet.
[4] M. Fernstrom,et al. Exercise, serum free tryptophan, and central fatigue. , 2006, The Journal of nutrition.
[5] M. Tisdale. Biology of cachexia. , 1997, Journal of the National Cancer Institute.
[6] J. Davis,et al. Effect of increased brain serotonergic activity on endurance performance in the rat. , 1992, Acta physiologica Scandinavica.
[7] S. Lightman,et al. Inflammatory Disease as Chronic Stress , 1998, Annals of the New York Academy of Sciences.
[8] J. Holm,et al. Obstructive Jaundice Results in Increased Liver Expression of Uncoupling Protein 2 and Intact Skeletal Muscle Glucose Metabolism in the Rat , 2002, Scandinavian journal of gastroenterology.
[9] J. Nortier,et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] F. Lévi,et al. [Study of circadian rhythms of activity by actometry: preliminary results in 30 patients with metastatic colorectal cancer]. , 1996, Pathologie-biologie.
[11] F. Lévi,et al. Non‐invasive estimation of the circadian rhythm in serum cortisol in patients with ovarian or colorectal cancer , 1998, International journal of cancer.
[12] T. Dinan,et al. Possible upregulation of hypothalamic 5-hydroxytryptamine receptors in patients with postviral fatigue syndrome. , 1992, BMJ.
[13] D G Stuart,et al. Neurobiology of muscle fatigue. , 1992, Journal of applied physiology.
[14] S. Gandevia. Spinal and supraspinal factors in human muscle fatigue. , 2001, Physiological reviews.
[15] M. Tisdale. Anorexia and Cachexia , 2005 .
[16] K. Kawasaki,et al. Caerulein, a cholecystokinin-related peptide, depresses somatic function via the vagal afferent system. , 1983, Life sciences.
[17] K. Lesch,et al. Enhancement of serotonin transporter function by tumor necrosis factor alpha but not by interleukin-6 , 1998, Neurochemistry International.
[18] M. Tisdale. Wasting in cancer. , 1999, The Journal of nutrition.
[19] S. Dickerson,et al. Diurnal cortisol rhythm and fatigue in breast cancer survivors , 2005, Psychoneuroendocrinology.
[20] David Spiegel,et al. Circadian disruption in cancer: a neuroendocrine-immune pathway from stress to disease? , 2003, Brain, Behavior, and Immunity.
[21] R J Maughan,et al. Evidence for a possible role of 5‐hydroxytryptamine in the genesis of fatigue in man: administration of paroxetine, a 5‐HT re‐uptake inhibitor, reduces the capacity to perform prolonged exercise , 1992, Experimental physiology.
[22] P. Dagnelie,et al. Randomized clinical trial of adenosine 5'-triphosphate in patients with advanced non-small-cell lung cancer. , 2000, Journal of the National Cancer Institute.
[23] G. Priore,et al. Adrenal function following high-dose steroids in ovarian cancer patients. , 1995, Gynecologic oncology.
[24] F. Lévi,et al. Disruption of the circadian patterns of serum cortisol in breast and ovarian cancer patients: relationships with tumour marker antigens. , 1996, British Journal of Cancer.
[25] R. Dantzer,et al. Cytokine-induced sickness behaviour: mechanisms and implications , 2002, Trends in Neurosciences.
[26] J. Davis,et al. Effects of Branched-Chain Amino Acids and Carbohydrate on Fatigue During Intermittent, High-Intensity Running , 1999, International journal of sports medicine.
[27] P. Andrews,et al. Temporal interrelationships among fatigue, circadian rhythm and depression in breast cancer patients undergoing chemotherapy treatment , 2002, Supportive Care in Cancer.
[28] P Hassmén,et al. Effect of branched-chain amino acid supplementation on mental performance. , 1991, Acta physiologica Scandinavica.
[29] P. Jacobsen,et al. Distinguishing fatigue and depression in patients with cancer. , 2003, Seminars in clinical neuropsychiatry.
[30] Z. Kronfol,et al. Circadian Immune Measures in Healthy Volunteers: Relationship to Hypothalamic-Pituitary-Adrenal Axis Hormones and Sympathetic Neurotransmitters , 1997, Psychosomatic medicine.
[31] L. Blackshaw,et al. Effects of 5-hydroxytryptamine on discharge of vagal mucosal afferent fibres from the upper gastrointestinal tract of the ferret. , 1993, Journal of the autonomic nervous system.
[32] D. McMillan,et al. The correlation between fatigue, physical function, the systemic inflammatory response, and psychological distress in patients with advanced lung cancer , 2005, Cancer.
[33] H. Withers,et al. Induction of acute phase gene expression by brain irradiation. , 1995, International journal of radiation oncology, biology, physics.
[34] M. Sahoo,et al. Cortisol hypersecretion in unipolar major depression with melancholic and psychotic features: Dopaminergic, noradrenergic and thyroid correlates , 2007, Psychoneuroendocrinology.
[35] E. Bosmans,et al. Increased 24‐hour urinary cortisol excretion in patients with post‐traumatic stress disorder and patients with major depression, but not h patients with fibromyalgia , 1998, Acta psychiatrica Scandinavica.
[36] M. Swain,et al. Suppression of hypothalamic-pituitary-adrenal axis responsiveness to stress in a rat model of acute cholestasis. , 1993, The Journal of clinical investigation.
[37] J. Bellanti,et al. Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndrome. , 1999, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[38] C. Fürst,et al. Symptoms in advanced cancer: relationship to endogenous cortisol levels , 2003, Palliative medicine.
[39] J. Davis,et al. Neuroendocrine and substrate responses to altered brain 5-HT activity during prolonged exercise to fatigue. , 1993, Journal of applied physiology.
[40] M. Kris,et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] C. Nemeroff,et al. Neurobehavioral Effects of Interferon-α in Cancer Patients: Phenomenology and Paroxetine Responsiveness of Symptom Dimensions , 2002, Neuropsychopharmacology.
[42] L. Staudt,et al. Clinical Trials and Observations , 2007 .
[43] G. Morrow,et al. Management of Cancer-Related Fatigue , 2005, Cancer investigation.
[44] R. Aquilani,et al. Altered muscle energy metabolism in post-absorptive patients with chronic renal failure. , 1997, Scandinavian journal of urology and nephrology.
[45] D. Cella,et al. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. , 1997, Journal of pain and symptom management.
[46] R. Stern,et al. Reduction in serum cortisol after platinum based chemotherapy for cancer: a role for the HPA axis in treatment-related nausea? , 2002, Psychophysiology.
[47] Circadian function in patients with advanced non-small-cell lung cancer , 2005, British Journal of Cancer.
[48] M. Antoni,et al. Dysregulated expression of tumor necrosis factor in chronic fatigue syndrome: interrelations with cellular sources and patterns of soluble immune mediator expression. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[49] E. Bruera,et al. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. , 2004, Cytokine.
[50] D. Hallahan,et al. The role of cytokines in radiation oncology. , 1993, Important advances in oncology.
[51] S. Ferketich,et al. The Development of an Instrument to Measure the Subjective Dimension of Fatigue , 1989 .
[52] J. Griggs,et al. Effect of paroxetine hydrochloride (Paxil®) on fatigue and depression in breast cancer patients receiving chemotherapy , 2005, Breast Cancer Research and Treatment.
[53] G. Demetri,et al. Comparable efficacy of epoetin alfa for anemic cancer patients receiving platinum- and nonplatinum-based chemotherapy: a retrospective subanalysis of two large, community-based trials. , 2002, The oncologist.
[54] P. Platen,et al. Influence of paroxetine, branched-chain amino acids and tyrosine on neuroendocrine system responses and fatigue in humans. , 1998, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[55] H. Kraemer,et al. Diurnal cortisol rhythm as a predictor of breast cancer survival. , 2000, Journal of the National Cancer Institute.
[56] A. Chaudhuri,et al. Fatigue in neurological disorders , 2004, The Lancet.
[57] D. Laude,et al. Effects of conditioned running on plasma, liver and brain tryptophan and on brain 5‐hydroxytryptamine metabolism of the rat , 1985, British journal of pharmacology.
[58] M. Perlis,et al. Cancer-related fatigue and sleep disorders. , 2007, The oncologist.
[59] J. Krueger,et al. Vagotomy Blocks the Induction of Interleukin-1β (IL-1β) mRNA in the Brain of Rats in Response to Systemic IL-1β , 1998, The Journal of Neuroscience.
[60] Norihiro Sadato,et al. Mechanisms underlying fatigue: a voxel-based morphometric study of chronic fatigue syndrome , 2004, BMC neurology.
[61] S. Maier,et al. Cytokines for psychologists: implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. , 1998, Psychological review.
[62] D. Perrett,et al. Effect of sustained exercise on plasma amino acid concentrations and on 5-hydroxytryptamine metabolism in six different brain regions in the rat. , 1989, Acta physiologica Scandinavica.
[63] G. Chrousos,et al. Sleep, the hypothalamic-pituitary-adrenal axis, and cytokines: multiple interactions and disturbances in sleep disorders. , 2002, Endocrinology and metabolism clinics of North America.
[64] J. Hill,et al. Stimulation of vagal afferents inhibits locomotion in mesencephalic cats. , 1993, Journal of applied physiology.
[65] Patricia A. Ganz,et al. Fatigue and Proinflammatory Cytokine Activity in Breast Cancer Survivors , 2002, Psychosomatic medicine.
[66] P. Hinds,et al. NCCN Practice Guidelines for Cancer-Related Fatigue. , 2000, Oncology.
[67] K. Blesch,et al. Correlates of fatigue in people with breast or lung cancer. , 1991, Oncology nursing forum.
[68] James F. Jones,et al. Chronic fatigue syndrome: identification of distinct subgroups on the basis of allergy and psychologic variables. , 1998, The Journal of allergy and clinical immunology.
[69] D. Cella,et al. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. , 1997, Seminars in hematology.
[70] M. Goldberg,et al. EFFECT OF INFLAMMATORY CYTOKINES ON HYPOXIA-INDUCED ERYTHROPOIETIN PRODUCTION , 1992 .
[71] C. Kilts,et al. Alterations in corticotropin-releasing factor-like immunoreactivity in discrete rat brain regions after acute and chronic stress , 1986, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[72] A. Berger,et al. Patterns of fatigue and activity and rest during adjuvant breast cancer chemotherapy. , 1998, Oncology nursing forum.
[73] J. Krueger,et al. Subdiaphragmatic vagotomy blocks the sleepand fever-promoting effects of interleukin-1β. , 1997, American journal of physiology. Regulatory, integrative and comparative physiology.
[74] F. Dhabhar,et al. The role of adrenocorticoids as modulators of immune function in health and disease: neural, endocrine and immune interactions , 1997, Brain Research Reviews.
[75] James F. Jones,et al. Chronic fatigue syndrome: a working case definition. , 1988, Annals of internal medicine.
[76] A. Paintal. Sensations From J Receptors , 1995 .
[77] A. Cleare,et al. Hypothalamo-pituitary-adrenal axis dysfunction in chronic fatigue syndrome, and the effects of low-dose hydrocortisone therapy. , 2001, The Journal of clinical endocrinology and metabolism.
[78] P. Ganz,et al. Altered Cortisol Response to Psychologic Stress in Breast Cancer Survivors With Persistent Fatigue , 2005, Psychosomatic medicine.
[79] S. Shirreffs,et al. The effect of acute branched-chain amino acid supplementation on prolonged exercise capacity in a warm environment , 2004, European Journal of Applied Physiology.
[80] Q. Springer-Verlag. Fatigue, depression and quality of life in cancer patients: how are they related? , 1998 .
[81] S. Henriksen,et al. Effects of corticotropin-releasing factor and growth hormone-releasing factor on sleep and activity in rats. , 1986, Neuroendocrinology.
[82] R. Dantzer,et al. Inhibition of vagally mediated immune-to-brain signaling by vanadyl sulfate speeds recovery from sickness. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[83] S. Sisto,et al. Reduced oxidative muscle metabolism in chronic fatigue syndrome , 1996, Muscle & nerve.
[84] J. Groopman,et al. Chemotherapy-induced anemia in adults: incidence and treatment. , 1999, Journal of the National Cancer Institute.
[85] C. Iber,et al. Extreme dyspnea from unilateral pulmonary venous obstruction. Demonstration of a vagal mechanism and relief by right vagotomy. , 1987, The American review of respiratory disease.
[86] Stefano Iacobelli,et al. Elevated Serum Cytokines Correlated with Altered Behavior, Serum Cortisol Rhythm, and Dampened 24-Hour Rest-Activity Patterns in Patients with Metastatic Colorectal Cancer , 2005, Clinical Cancer Research.
[87] M. Sawka,et al. Branched-chain amino acid supplementation and human performance when hypohydrated in the heat. , 2004, Journal of applied physiology.
[88] M. Mormont,et al. Contribution of the rest–activity circadian rhythm to quality of life in cancer patients , 2002, Chronobiology international.
[89] A. Steiger,et al. Effects of intravenous corticotropin-releasing hormone upon sleep-related growth hormone surge and sleep EEG in man. , 1988, Neuroendocrinology.
[90] T. Dinan,et al. Blunted adrenocorticotropin and Cortisol responses to corticotropin‐releasing hormone stimulation in chronic fatigue syndrome , 1998, Acta psychiatrica Scandinavica.
[91] P. Cowen,et al. Increased brain serotonin function in men with chronic fatigue syndrome , 1997, BMJ.
[92] P. Flynn,et al. Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[93] G. Lyman,et al. Fatigue in women receiving adjuvant chemotherapy for breast cancer: characteristics, course, and correlates. , 1999, Journal of pain and symptom management.
[94] J. Krueger,et al. Vagotomy attenuates but does not prevent the somnogenic and febrile effects of lipopolysaccharide in rats. , 1998, The American journal of physiology.
[95] F. Lévi,et al. Cancer-associated alteration of circadian rhythms in carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) in humans. , 1986, Anticancer research.
[96] F. Lévi,et al. Rhythm alteration in patients with metastatic breast cancer and poor prognostic factors , 2005, Journal of Cancer Research and Clinical Oncology.
[97] Eva Blomstrand,et al. Branched-chain amino acids and central fatigue. , 2006, The Journal of nutrition.
[98] V. Mock,et al. Assessment and management of cancer-related fatigue in adults , 2003, The Lancet.
[99] T. Dinan,et al. Blunted serotonin-mediated activation of the hypothalamic-pituitary-adrenal axis in chronic fatigue syndrome , 1997, Psychoneuroendocrinology.
[100] G. Kemp,et al. Heterogeneity in chronic fatigue syndrome: evidence from magnetic resonance spectroscopy of muscle , 1998, Neuromuscular Disorders.
[101] S. Jamar. Fatigue in Women Receiving Chemotherapy for Ovarian Cancer , 1989 .
[102] H. Poulsen,et al. Assessment of the hypothalamo-pituitary-adrenal axis in patients treated with radiotherapy and chemotherapy for childhood brain tumor. , 2003, The Journal of clinical endocrinology and metabolism.
[103] J. Singer,et al. Phase I-II trial of pentoxifylline for the prevention of transplant- related toxicities following bone marrow transplantation [published erratum appears in Blood 1992 Jun 15;79(12):3397] [see comments] , 1991 .
[104] W. Jelkmann,et al. Modulation of the production of erythropoietin by cytokines: in vitro studies and their clinical implications. , 1990, Contributions to nephrology.
[105] A. Cleare,et al. The neuroendocrinology of chronic fatigue syndrome. , 2003, Endocrine reviews.
[106] F. Chaouloff. Physiopharmacological interactions between stress hormones and central serotonergic systems , 1993, Brain Research Reviews.
[107] M. Kalia. Effects of certain cerebral lesions on the J reflex , 1973, Pflügers Archiv.
[108] R. Kurzrock,et al. Cytokine deregulation in cancer. , 2001, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[109] J. Pickar. The thromboxane A2 mimetic U-46619 inhibits somatomotor activity via a vagal reflex from the lung. , 1998, The American journal of physiology.
[110] G. Peluso,et al. Skeletal muscle metabolism in physiology and in cancer disease , 2003, Journal of cellular biochemistry.
[111] C. Begg,et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. , 1980, The American journal of medicine.
[112] E. Jones. Relief from profound fatigue associated with chronic liver disease by long-term ondansetron therapy , 1999, The Lancet.
[113] H. Coleridge,et al. Afferent vagal C fibre innervation of the lungs and airways and its functional significance. , 1984, Reviews of physiology, biochemistry and pharmacology.
[114] F. Holsboer,et al. Acute Cortisol Administration Promotes Sleep Intensity in Man , 2004, Neuropsychopharmacology.
[115] G. Bleijenberg,et al. The effect of granisetron, a 5-HT3 receptor antagonist, in the treatment of chronic fatigue syndrome patients--a pilot study. , 2003, Netherlands Journal of Medicine.
[116] D. McCloskey. Kinesthetic sensibility. , 1978, Physiological reviews.
[117] Jacobsen,et al. Is Fatigue a Long-term Side Effect of Breast Cancer Treatment? , 1999, Cancer control : journal of the Moffitt Cancer Center.
[118] D. Greenberg,et al. Treatment-related fatigue and serum interleukin-1 levels in patients during external beam irradiation for prostate cancer. , 1993, Journal of pain and symptom management.
[119] P. Sawchenko,et al. Differential regulation of corticotropin-releasing factor mRNA in rat brain regions by glucocorticoids and stress , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[120] R. Crow,et al. A qualitative study to explore the concept of fatigue/tiredness in cancer patients and in healthy individuals. , 1996, Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.
[121] P. Ganz,et al. Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[122] W. Saris,et al. Ingestion of branched‐chain amino acids and tryptophan during sustained exercise in man: failure to affect performance. , 1995, The Journal of physiology.
[123] P. Blower,et al. Effect of Granisetron on Performance Status during High-Dose Interferon Therapy , 1999, Oncology.
[124] D. Gemsa,et al. Effects of interferon-gamma, interleukin-1 beta, and tumor necrosis factor-alpha on the serotonin metabolism in the nucleus raphe dorsalis of the rat. , 1997, Journal of neural transmission.
[125] M. R. Visser,et al. Fatigue, depression and quality of life in cancer patients: how are they related? , 1998, Supportive Care in Cancer.
[126] M. Simmonds,et al. Differences in physical performance between men and women with and without lymphoma. , 2003, Archives of physical medicine and rehabilitation.
[127] S. Bailey,et al. Branched-chain amino acids prolong exercise during heat stress in men and women. , 1998, Medicine and science in sports and exercise.
[128] L. Färber,et al. Treatment of chronic fatigue syndrome with 5-HT3 receptor antagonists--preliminary results. , 2000, Scandinavian Journal of Rheumatology. Supplement.
[129] P. Hassmén,et al. Influence of ingesting a solution of branched-chain amino acids on perceived exertion during exercise. , 1997, Acta physiologica Scandinavica.
[130] P. Grasby,et al. Brain 5-HT1A receptor binding in chronic fatigue syndrome measured using positron emission tomography and [11C]WAY-100635 , 2005, Biological Psychiatry.
[131] M. Weisman,et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. , 2003, Arthritis and rheumatism.
[132] Joseph R. Bertino,et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. , 1980, The American journal of medicine.
[133] G. Aguilera. Regulation of Pituitary ACTH Secretion during Chronic Stress , 1994, Frontiers in Neuroendocrinology.
[134] S. Wessely,et al. Contrasting neuroendocrine responses in depression and chronic fatigue syndrome , 1995, Biological Psychiatry.
[135] M. Hotopf,et al. Chronic fatigue and its syndromes , 1998 .
[136] E. Tornquist,et al. Key Aspects of Comfort: Management of Pain, Fatigue, and Nausea , 1989 .
[137] E. Newsholme,et al. The role of tryptophan in fatigue in different conditions of stress. , 1999, Advances in experimental medicine and biology.
[138] P. Andrews,et al. Fatigue associated with cancer and its treatment , 2002, Supportive Care in Cancer.
[139] M. Wichers,et al. The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. , 2002, The international journal of neuropsychopharmacology.
[140] M. Demitrack,et al. Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. , 1991, The Journal of clinical endocrinology and metabolism.
[141] S. Landau,et al. An investigation of hypothalamic-pituitary-adrenal axis hyperactivity in anorexia nervosa: the role of CRH and AVP. , 2007, Journal of psychiatric research.
[142] J Lellouch,et al. Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[143] A qualitative study to explore the concept of fatigue/ tiredness in cancer patients and in healthy individuals , 1998 .
[144] M. Opp,et al. Corticotropin-releasing hormone (CRH) as a regulator of waking , 2001, Neuroscience & Biobehavioral Reviews.
[145] J. Payne. The trajectory of fatigue in adult patients with breast and ovarian cancer receiving chemotherapy. , 2002, Oncology nursing forum.
[146] A. Chaudhuri,et al. Fatigue and basal ganglia , 2000, Journal of the Neurological Sciences.
[147] A. Farmer,et al. Heterogeneity of serum tryptophan concentration and availability to the brain in patients with the chronic fatigue syndrome , 2005, Journal of psychopharmacology.
[148] M. Dicato. Anemia in cancer: some pathophysiological aspects. , 2003, The oncologist.
[149] E. Hansson,et al. On the potential role of glutamate transport in mental fatigue , 2004, Journal of Neuroinflammation.
[150] A. Niijima,et al. The afferent discharges from sensors for interleukin 1 beta in the hepatoportal system in the anesthetized rat. , 1996, Journal of the autonomic nervous system.
[151] C. Kirschbaum,et al. The 'Trier Social Stress Test'--a tool for investigating psychobiological stress responses in a laboratory setting. , 1993, Neuropsychobiology.
[152] F. López‐Soriano,et al. Cytokines as mediators and targets for cancer cachexia. , 2006, Cancer treatment and research.
[153] L. Nail,et al. Fatigue and the cancer experience: the state of the knowledge. , 1994, Oncology nursing forum.
[154] R. Figlin,et al. Tumor necrosis factor: current clinical status and implications for nursing management. , 1988, Seminars in oncology nursing.
[155] J. Davis,et al. Possible mechanisms of central nervous system fatigue during exercise. , 1997, Medicine and science in sports and exercise.
[156] M. Opp,et al. Somnogenic and pyrogenic effects of interleukin-1beta and lipopolysaccharide in intact and vagotomized rats. , 1998, Life sciences.
[157] A. Paintal,et al. Vagal sensory receptors and their reflex effects. , 1973, Physiological reviews.
[158] J. Davis,et al. 438 EFFECTS OF A SEROTONIN (5-HT) AGONIST DURING PROLONGED EXERCISE TO FATIGUE IN HUMANS , 1993 .
[159] V. Mock,et al. Exercise as an intervention for cancer-related fatigue. , 2004, Physical therapy.
[160] D. Eckland,et al. Paradoxical responses of hypothalamic corticotropin-releasing factor (CRF) messenger ribonucleic acid (mRNA) and CRF-41 peptide and adenohypophysial proopiomelanocortin mRNA during chronic inflammatory stress. , 1992, Endocrinology.
[161] E. Newsholme,et al. Tryptophan, 5-hydroxytryptamine and a possible explanation for central fatigue. , 1995, Advances in experimental medicine and biology.
[162] Eva Blomstrand,et al. A role for branched-chain amino acids in reducing central fatigue. , 2006, The Journal of nutrition.
[163] R. Omdal,et al. The effect of interleukin-1 blockade on fatigue in rheumatoid arthritis—a pilot study , 2005, Rheumatology International.
[164] J. Phair,et al. Serum neopterin and interleukin-6 levels in chronic fatigue syndrome. , 1990, The Journal of infectious diseases.
[165] J. Leiper,et al. Paroxetine administration to influence human exercise capacity, perceived effort or hormone responses during prolonged exercise in a warm environment , 2004, Experimental physiology.
[166] L C Harrison,et al. Diurnal rhythms of pro-inflammatory cytokines: regulation by plasma cortisol and therapeutic implications. , 1998, Cytokine.
[167] T. Lundeberg,et al. Activation of Vagal Afferents after Intravenous Injection of Interleukin-1β: Role of Endogenous Prostaglandins , 1998, The Journal of Neuroscience.
[168] F. Lévi,et al. Circadian‐system alterations during cancer processes: A review , 1997, International journal of cancer.
[169] P. Hassmén,et al. Administration of branched-chain amino acids during sustained exercise — effects on performance and on plasma concentration of some amino acids , 2004, European Journal of Applied Physiology and Occupational Physiology.
[170] M. Swain,et al. Defective corticotropin‐releasing hormone mediated neuroendocrine and behavioral responses in cholestatic rats: Implications for cholestatic liver disease–related sickness behaviors , 1995, Hepatology.
[171] L. Blackshaw,et al. Effects of 5-hydroxytryptamine (5-HT) on the discharge of vagal mechanoreceptors and motility in the upper gastrointestinal tract of the ferret. , 1993, Journal of the autonomic nervous system.
[172] D. Cella,et al. Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.